Dr Sanne Lugthart, leading haematologist at University Hospitals Bristol and Weston NHS Foundation Trust, commented, “This has been an area of great progress for patients and for research. I have worked with the Sanius team on several patient-centric programmes that have demonstrated better outcomes, improved access, and truly addressed some unmet needs for patients and carers.”
Vincent Sai, CEO of Modality Group, added, “We see this as the future for patients across our footprint in the UK, which was a key reason for our strategic partnership with Sanius Health in supporting key disease areas.” Indeed, such approaches align closely with Sanius’ collaboration with Modality Partnership to enhance chronic condition management, particularly asthma. By leveraging AI-driven technologies and insights from wearable devices, this partnership aims to improve patient outcomes and reduce the burden on NHS resources. An upcoming study approved by IRAS, in collaboration with Portsmouth NHS Trust, will further focus on demonstrating the impact of digital tools in asthma management, empowering patients to actively monitor their symptoms, and receive timely feedback. Together, these initiatives illustrate the potential of technology to transform healthcare delivery and support patients in managing their conditions more effectively
From a patient perspective, the Sanius wearable, patient app, and medical data ecosystem have had significant outcomes across multiple disease areas. Bob Perry, an active member of our Waldenstrom’s Macroglobulinaemia (WM) community, shared that, “As a blood cancer patient of nine years, I started wearing my Sanius-sponsored watch in January. It is invaluable for me as I can monitor my ECG, O2 intake, temperature, sleep, and fitness, and tie these in with the accompanying app. I can then provide this information to my consultant when I have my regular check-ups, and it provides her with more than just the vitals ‘on the day’.”
Bob continued, “Already this year, I was able to bring some Atrial Fibrillation to her attention. Without the watch, I wouldn’t have known about it. This is a massive step forward not only for me being more involved in my care but also in providing ongoing and current information to my healthcare team.”
Similarly in Sickle Cell Disease (SCD), Reia DaCosta commented, “As a mother of three and someone living with sickle cell disease, I never imagined that a small device on my wrist could make such a significant impact on my life. Smartwatches always seemed like luxury gadgets for tech enthusiasts or fitness buffs—certainly not a necessity for someone like me. However, joining the Sanius Health ecosystem opened my eyes to the potential of these devices, and I can now confidently say that my smartwatch has not only improved my daily life but quite literally saved it.”
Opportunities for Wearable Tech in Healthcare and Outcomes Improvement
The government’s 10-year plan to revitalise the NHS emphasises a significant investment in wearable technology. This initiative aims to empower patients to monitor their health conditions, such as diabetes and heart disease, from home, thereby reducing the need for hospital visits and enabling more proactive care. By leveraging wearable tech, the NHS aspires to alleviate pressures on healthcare services and enhance patient outcomes through real-time data collection.
Sanius Health’s commitment to supporting patients with its ecosystem has already seen notable results across the healthcare landscape. Indeed, closely aligning with the NHS’s focus on both moving care from hospitals to the community and creating more prevention-centric approaches, its work has to date supported the development of key predictive algorithms to support early acute event detection, using data collected from wearables and patient-reported outcomes.
These algorithms have demonstrated the ability to predict 84% of acute events such as vaso-occlusive crises (VOCs) for patients, as presented at the American Society for Haematology Meeting 2023. From here, we have continued to explore ways to enhance patient quality of life by identifying critical symptoms and facilitating timely interventions. For example, in diseases such as WM, the team’s work in wearable metric insights has identified potential correlations between these variables and key symptoms relevant to disease states and patient quality of life, highlighting key targets for remote monitoring and patient health deterioration prevention in real-world settings.
